Drugs / GSK5764227
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07277270 | Dec 2025 → Jul 2026 overdue | neoplasm | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 1 | NCT05277051 | Mar 2022 → Aug 2027 expected | neoplasm | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06885034 | Jun 2025 → Jan 2028 expected | digestive system neoplasm | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07408063 | Apr 2026 → Jun 2030 expected | head and neck squamous cell carcinoma | University Health Network, Toronto | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK5764227 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07408063 ↗ |
| Action | Deplete | “delivers a toxin directly to cancer cells to destroy them while sparing healthy cells” NCT07277270 ↗ |
| Route | Intravenous | “All participants will receive GSK5764227 monotherapy at a starting dose of 8 mg/kg Intravenously every 3 weeks (IV Q3W) in a 21-day treatment cycle.” NCT07408063 ↗ |